Virtual Library

Start Your Search

Dagmar Myšíková



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-43 - The Significance of NY-ESO 1 Seropositivity and Influence on NSCLC Patients Survival (ID 2654)

      08:00 - 18:00  |  Author(s): Dagmar Myšíková

      • Abstract

      Background

      Lung cancer is the leading cause of cancer mortality worldwide. Understanding biological processes of specific antitumor immune response remains of an eminent interest and represents necessity for designing successful antitumor immunotherapeutic strategies. In our previous study published in JTO 2017, we focused on the humoral component of the specific antitumor response and prospectively analysed serum frequencies of antitumor antibodies against NY-ESO-1, Her2/neu and MAGE-A4 antigens in 121 patients with NSCLC. Here it was shown for the first time that tobacco smoking significantly increases the frequency of NY-ESO-1 antibodies in sera of smokers in comparison to ex-smokers and non-smokers. In our current follow-up study, we plan to describe the significance of NY-ESO 1 seropositivity and influence on NSCLC patients survival. We suppose to have data completed during June 2019 (we are waiting for the 5-year observation period). We would like to apply for Late-Breaking Abstract privileges and the opportunity to present these novel promising data.

      Method

      Between 2009 and 2014 we prospectively analyzed the serum frequencies of NY-ESO-1 antibodies and corresponding antigen expression in tumors of 121 non-small cell lung cancer (NSCLC) patients undergoing surgery without prior neoadjuvant chemotherapy and compared them with 57 control age-matched patients with no history of malignant disease, each with no sign of malignancy on chest X-ray. In addition to pulmonary X-ray, a panel of tumor markers (CEA, TPA, NSE, SCC, CYFRA 21-1) was used to compare the group of cancer patients and the group of control patients. The complete set of samples for NY-ESO-1 analyses which includes serum, tumoral and non-tumoral tissue was obtained only for 40 patients. Nowadays we are finishing a 5-year observation period after surgery for primary tumor and we plan to complete a statistical analysis of all data by June 2019. We would like to present results of our follow-up study on WCLC 2019.

      Result

      We suppose to have data completed during June 2019 and we apply for Late-Breaking Abstract privileges. Thank you for considering our request.

      Conclusion

      We suppose to have data completed during June 2019 and we apply for Late-Breaking Abstract privileges. Thank you for considering our request.